CD33 chimeric antigen receptor T cells

CD33 chimeric antigen receptor (CAR) T cells are a cell-based immunotherapy being developed for the treatment of acute myeloid leukemia (AML). This biologic therapy consists of autologous or allogeneic T cells genetically modified to express a CAR targeting CD33 (Siglec-3), a transmembrane receptor found on over 80% of AML blasts. The CAR constructs typically include a single-chain variable fragment (scFv) derived from anti-CD33 antibodies (such as gemtuzumab or lintuzumab), a costimulatory domain (CD28 or 4-1BB), and a CD3ζ signaling domain. While preclinical studies have shown potent anti-leukemic activity, clinical development faces challenges due to on-target, off-tumor toxicity, as CD33 is also expressed on normal myeloid progenitors, leading to potential severe myelosuppression.

Other names

CD33-directed CAR-T cellsCD-33-directed CAR-T cellsCD 33-directed CAR-T cellsanti-CD33 CAR-T cellsanti-CD-33 CAR-T cellsanti-CD 33 CAR-T cells